AbbVie on the Brink of Billion-Dollar Acquisition of Apogee Therapeutics! The Post-Humira Era is Taking Shape!

AbbVie is close to a $10.9 billion acquisition of Apogee Therapeutics to secure its core immunology segment With the recent FDA approvals for Skinvive and Decnupaz, the company reduces its reliance on existing blockbusters The development of next-generation antibody-drug conjugates aims to set new standards in oncology The US pharmaceutical giant AbbVie (ABBV) is strategically under pressure. Following the patent expiration of its long-time revenue driver Humira, the company is focusing on expanding its pipeline. As reported by the Financial...